Original Article
Effect of Dronedarone on Cardiovascular Events in Atrial Fibrillation
N Engl J Med 2009; 360:668-678February 12, 2009
- Abstract
Background
Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation.
Methods
We conducted a multicenter trial to evaluate the use of dronedarone in 4628 patients with atrial fibrillation who had additional risk factors for death. Patients were randomly assigned to receive dronedarone, 400 mg twice a day, or placebo. The primary outcome was the first hospitalization due to cardiovascular events or death. Secondary outcomes were death from any cause, death from cardiovascular causes, and hospitalization due to cardiovascular events.
Results
The mean follow-up period was 21±5 months, with the study drug discontinued prematurely in 696 of the 2301 patients (30.2%) receiving dronedarone and in 716 of the 2327 patients (30.8%) receiving placebo, mostly because of adverse events. The primary outcome occurred in 734 patients (31.9%) in the dronedarone group and in 917 patients (39.4%) in the placebo group, with a hazard ratio for dronedarone of 0.76 (95% confidence interval [CI], 0.69 to 0.84; P<0.001). There were 116 deaths (5.0%) in the dronedarone group and 139 (6.0%) in the placebo group (hazard ratio, 0.84; 95% CI, 0.66 to 1.08; P=0.18). There were 63 deaths from cardiovascular causes (2.7%) in the dronedarone group and 90 (3.9%) in the placebo group (hazard ratio, 0.71; 95% CI, 0.51 to 0.98; P=0.03), largely due to a reduction in the rate of death from arrhythmia with dronedarone. The dronedarone group had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash, and an increased serum creatinine level than the placebo group. Rates of thyroid- and pulmonary-related adverse events were not significantly different between the two groups.
Conclusions
Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation. (ClinicalTrials.gov number, NCT00174785.)
Media in This Article
Figure 1
Randomization and Follow-up of the Study Patients.Figure 2
Kaplan–Meier Cumulative Incidences of the Primary and Secondary Outcomes.Article Activity
- Article
Atrial fibrillation is the most common type of cardiac arrhythmia requiring medical care, with a prevalence of almost 1% in the adult population in the United States.1 Its prevalence increases with age, affecting 3.8% of the U.S. population over 60 years of age and 9.0% of the population older than 80 years. Over the past two decades, hospitalizations for atrial fibrillation in the United States have increased by a factor of two to three, resulting in a substantial public health burden.2 Despite advances in nonpharmacologic therapy,3 many symptomatic patients receive medical treatment for rhythm control. Currently available antiarrhythmic agents are limited by either their modest efficacy or their potential for serious ventricular proarrhythmia or extracardiac toxic effects. Furthermore, no currently available antiarrhythmic treatment has been shown to reduce the rate of hospitalization due to cardiovascular events in patients with atrial fibrillation.
Dronedarone is a benzofuran derivative with an electropharmacologic profile resembling that of amiodarone but with different relative effects on individual ion channels.4-7 The structural changes made to amiodarone to produce dronedarone include the removal of iodine and the addition of a methane–sulfonyl group.8 The latter change decreases lipophilicity, thus shortening the half-life (to approximately 24 hours) and reducing accumulation in tissue. These molecular changes were made with the intention of reducing the risk of amiodarone-associated thyroid-related and pulmonary disease.7,8 Dronedarone is hepatically metabolized and excreted in the feces.
In two randomized, controlled trials involving 1237 patients with atrial fibrillation or flutter, dronedarone was shown to be more effective than placebo in maintaining sinus rhythm and in controlling the ventricular rate during recurrences of atrial fibrillation.9 At 12 months of follow-up, rates of pulmonary, thyroid-related, and hepatic adverse effects were not significantly greater with dronedarone than with placebo. However, another study of dronedarone in patients with advanced symptomatic congestive heart failure, but without atrial fibrillation, was prematurely terminated because of an excess of deaths among patients taking dronedarone.10
ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from Any Cause in Patients with Atrial Fibrillation/Atrial Flutter) was designed to determine whether dronedarone would reduce the rate of the composite outcome of hospitalization due to cardiovascular events or death in patients with atrial fibrillation.
Methods
Details of the study protocol have been published previously.11 ATHENA was a randomized, double-blind, placebo-controlled trial conducted according to the Declaration of Helsinki at 551 centers in 37 countries. The institutional review board at each site approved the study, and all patients gave written informed consent. Enrollment of patients commenced in June 2005 and was completed on December 30, 2006.
The trial was sponsored by Sanofi-Aventis and designed by the steering committee (see the Supplementary Appendix, available with the full text of this article at NEJM.org) in collaboration with the sponsor. Data collection and management and statistical analysis were performed by the sponsor. The first draft of the report was written by the principal investigator (an academic author), and subsequent drafts were revised and edited by all the authors, who vouch for the accuracy and completeness of the data.
Study Population
Patients with paroxysmal or persistent atrial fibrillation or flutter were eligible if they met at least one of the following requirements: age of at least 70 years; arterial hypertension (with ongoing therapy involving at least two antihypertensive drugs of different classes); diabetes mellitus; previous stroke, transient ischemic attack, or systemic embolism; left atrial diameter greater than or equal to 50 mm, as measured on M-mode echocardiography; and left ventricular ejection fraction less than or equal to 40%. For each patient, a 12-lead electrocardiogram (ECG) showing atrial fibrillation or flutter and obtained within 6 months before randomization had to be available. A second 12-lead ECG within the same period had to show sinus rhythm.
During the course of the trial, overall mortality figures were lower than expected. Therefore, the steering committee elected to change the inclusion criteria to enrich the risk profile of the overall study population. On the basis of the revised criteria, patients 75 years of age or older were eligible, whether or not they had any previously specified risk factors, but patients 70 years of age or older were eligible only if they had one or more of the other risk factors. Patients younger than 70 years of age were no longer eligible. This protocol amendment was implemented on March 8, 2006.
Exclusion Criteria
Patients were ineligible for participation in the trial if they had any of the following cardiac conditions: permanent atrial fibrillation; an unstable hemodynamic condition (i.e., decompensated heart failure within the previous 4 weeks); New York Heart Association (NYHA) class IV congestive heart failure; planned major surgery; acute myocarditis; bradycardia with a heart rate of less than 50 beats per minute or a PR interval of more than 0.28 second; or previous clinically significant sinus-node disease, if the patient was not currently being treated with a pacemaker. General (noncardiac) exclusion criteria were as follows: any severe noncardiac illness limiting life expectancy; pregnancy, breast-feeding, or lack of adequate birth control among women of childbearing potential; a calculated glomerular filtration rate at baseline of less than 10 ml per minute; a potassium level of less than 3.5 mmol per liter, if not currently being corrected; and a requirement for concomitant medication that was prohibited (i.e., other class I or III antiarrhythmic drugs).
Enrollment and Follow-up
Patients could be enrolled while in sinus rhythm (if conversion had occurred either spontaneously or after electrical or pharmacologic cardioversion). Patients also could be enrolled while in atrial fibrillation or flutter, in which case they would be expected to undergo cardioversion after appropriate anticoagulation. Patients were randomly assigned, in a 1:1 ratio, to receive dronedarone, 400 mg twice a day, or placebo. Randomization was stratified according to center and by the presence or absence of atrial fibrillation or flutter at the time of randomization.
The follow-up schedule called for clinical evaluations at days 7 and 14 and at months 1, 3, 6, 9, and 12 and every 3 months thereafter. The trial was planned to have a minimum follow-up duration of 12 months; all patients were followed until the common end date of December 30, 2007.
Study Outcomes
The primary study outcome was the first hospitalization due to cardiovascular events or death from any cause. Any unplanned hospitalization (i.e., admission with an overnight stay in the hospital) was classified by the investigator as a hospitalization due to either cardiovascular or noncardiovascular causes.11 Deaths were categorized by means of blinded adjudication, according to a modified Hinkle and Thaler classification,12 into four categories: death from cardiac arrhythmia, death from nonarrhythmic cardiac causes, death from noncardiac vascular causes, and death from noncardiovascular causes. This classification scheme has been validated previously.13-15 Secondary study outcomes were death from any cause, death from cardiovascular causes, and first hospitalization due to cardiovascular events.
Statistical Analysis
On the basis of two large efficacy trials of dronedarone in patients with atrial fibrillation,8 the 1-year rate of hospitalization due to cardiovascular events in the placebo group was estimated to be 20%, a figure also reported in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.16 In order to have a statistical power of 80% to detect a 15% reduction with dronedarone in the rate of the primary outcome (under the exponential model at a two-sided alpha level of 0.05), 970 primary outcome events were estimated to be required. We aimed to observe approximately 260 deaths, which would allow for the estimate of the relative risk of death to be made with a precision of ±0.13 within an inclusion period of 1.5 years. To achieve these objectives, we anticipated that a minimum follow-up period of 1 year and a maximum follow-up period of 2.5 years (mean, 1.7), with enrollment of 2150 patients per group (4300 in total), would be necessary.
Prespecified analyses were performed according to the intention-to-treat principle. The times to the primary outcome of hospitalization due to cardiovascular events or death and to secondary outcomes were estimated with the use of the Kaplan–Meier method and compared by means of the log-rank test. All P values were two-tailed.
An independent data and safety monitoring board reviewed the study data regularly. One formal interim analysis was performed when half the originally expected primary outcome events had occurred.
Results
A total of 4628 patients were enrolled, of whom 2301 were randomly assigned to receive dronedarone and 2327 to receive placebo (Figure 1Figure 1
Randomization and Follow-up of the Study Patients.). The two groups were well matched with respect to baseline characteristics (Table 1Table 1
Baseline Characteristics of the Study Patients.). Overall, the mean age was 71.6 years, and 46.9% of participants were female. Twenty-five percent of patients had atrial fibrillation at randomization. The predominant underlying cardiovascular disease was hypertension, and there was evidence of structural heart disease in the majority of patients (59.6%) for whom the data were available.11 The left ventricular ejection fraction was quantified in 4544 patients, of whom 179 (3.9%) and 540 (11.9%) had an ejection fraction of less than 35% and less than 45%, respectively. There was a history of NYHA heart failure in 979 patients (21.2%): class II failure in 779 (17.1%) and class III in 200 (4.4%).The mean (±SD) duration of follow-up among all patients was 21±5 months, with a median of 22 months. The minimum follow-up duration was 1 year, and the maximum 2.5 years.
Primary Outcome
Among patients assigned to receive dronedarone, 734 (31.9%) had a primary outcome event, including 675 (29.3%) with a hospitalization due to cardiovascular events and 59 (2.6%) who died. In the placebo group, 917 patients (39.4%) had a primary outcome event. These included 859 (36.9%) with a first hospitalization due to cardiovascular events and 58 (2.5%) who died before hospitalization. The hazard ratio for the primary outcome in the dronedarone group was 0.76 (95% confidence interval [CI], 0.69 to 0.84; P<0.001) (Table 2Table 2
Study Outcomes. and Figure 2AFigure 2Kaplan–Meier Cumulative Incidences of the Primary and Secondary Outcomes.). Figure 3Figure 3
Hazard Ratios for the Primary Outcome, According to Selected Baseline Characteristics. shows that the effect of dronedarone on the primary outcome was consistent across a variety of important subgroups (which were not prespecified).Fatal Outcomes
Death from any cause was one of the three prespecified secondary outcomes. There were 116 deaths (in 5.0% of patients) in the dronedarone group and 139 (in 6.0%) in the placebo group (hazard ratio, 0.84; 95% CI, 0.66 to 1.08; P=0.18) (Table 2 and Figure 2B). Death was classified, on the basis of blinded adjudication, as being cardiovascular in origin in 63 patients (2.7%) in the dronedarone group and 90 (3.9%) in the placebo group (hazard ratio, 0.71; 95% CI, 0.51 to 0.98; P=0.03) (Table 2 and Figure 2C). There were 26 deaths from cardiac arrhythmia (in 1.1% of patients) in the dronedarone group and 48 (in 2.1%) in the placebo group (hazard ratio, 0.55; 95% CI, 0.34 to 0.88; P=0.01) (Table 2).
Hospitalization Due to Cardiovascular Events
In the dronedarone group, 675 patients (29.3%) had a first hospitalization due to cardiovascular events, as compared with 859 patients (36.9%) in the placebo group (hazard ratio, 0.74; 95% CI, 0.67 to 0.82; P<0.001) (Table 2 and Figure 2D). This reduction in the rate of hospitalization due to cardiovascular events was driven mainly by a reduction in the number of hospitalizations for atrial fibrillation. There were no significant differences between the two groups in the number of hospitalizations for heart failure or for ventricular arrhythmia or nonfatal cardiac arrest. There were also significantly fewer hospitalizations for an acute coronary syndrome in the dronedarone group (Table 2). When all outcome events (hospitalization due to any cardiovascular event or death from any cause) during the study period were considered, the effect of dronedarone was consistent: 1253 patients (54.5%) had an event in the dronedarone group, as compared with 1668 (71.7%) in the placebo group (hazard ratio, 0.76; 95% CI, 0.68 to 0.84; P<0.001).
Study Discontinuation and Adverse Events
The study drug was prematurely discontinued in 696 (30.2%) of patients receiving dronedarone, as compared with 716 (30.8%) of those receiving placebo. The main reasons were adverse events (in 12.7% of patients in the dronedarone group vs. 8.1% in the placebo group), subject's request (7.5% in each group), and other reasons (9.4% in the dronedarone group vs. 14.4% in the placebo group). The imbalance in the “other reasons” category was mainly due to the more-frequent investigator initiation of study-disallowed antiarrhythmic medication or recurrent atrial fibrillation in the placebo group.
The incidence of important treatment-emergent adverse events and laboratory abnormalities is shown in Table 3Table 3
Selected Adverse Events and Laboratory Abnormalities in Patients Who Received the Study Drug.. Bradycardia, QT-interval prolongation, diarrhea, nausea, rash, and an increase in the serum creatinine level were significantly more common in the dronedarone group than in the placebo group. Pulmonary symptoms, interstitial lung disease, and abnormalities of thyroid function were not significantly more common with dronedarone than with placebo.One case of torsades de pointes tachycardia was reported in a 66-year-old female patient receiving dronedarone. After she had been resuscitated from out-of-hospital ventricular fibrillation, an episode of torsades de pointes was documented in the intensive care unit. Subsequently, the patient underwent implantation of a defibrillator and was discharged home.
Discussion
In this trial, the use of dronedarone significantly reduced the risk of hospitalization due to cardiovascular events or death in patients with paroxysmal or persistent atrial fibrillation or flutter. A significant reduction in death from any cause was not demonstrated (hazard ratio for dronedarone vs. placebo, 0.84; P=0.18). However, there was a significant reduction in the rate of the prespecified secondary outcome of death from cardiovascular causes. The rate of death from cardiac arrhythmia was also significantly reduced with dronedarone.
In two previous randomized studies, dronedarone was reported to be more effective than placebo for maintenance of sinus rhythm.9 Specifically, the time to first recurrence of atrial fibrillation was increased from a median of 53 days in the control group to 116 days in the dronedarone group. Also, the drug decreased the mean ventricular rate during the recurrence of atrial fibrillation, from 117 to 103 beats per minute (P<0.001). It is likely that both prevention of recurrent atrial fibrillation and rate control during the arrhythmia were responsible for reducing the rate of hospitalization due to cardiovascular events in the present trial.
Another previous study, the Anti-arrhythmic Trial with Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease (ANDROMEDA), was terminated prematurely because of increased mortality with dronedarone.10 Patients enrolled in ANDROMEDA had symptomatic congestive heart failure, a left ventricular ejection fraction of 35% or less, and recent hospitalization with new or worsening heart failure. The excess mortality was predominantly related to congestive heart failure.
The difference in outcome between ATHENA and ANDROMEDA may be a consequence of the fact that ANDROMEDA enrolled only patients with advanced heart failure and recent decompensation leading to hospitalization. In contrast, ATHENA specifically excluded patients who had either hemodynamic instability or severe (NYHA class IV) heart failure. It is therefore possible that dronedarone increases cardiovascular mortality among patients with advanced and recently decompensated congestive heart failure but reduces cardiovascular mortality in patients with less severe heart failure. In the present trial, 21% of patients did have a history of congestive heart failure with NYHA class II or III symptoms, and 12% had a left ventricular ejection fraction less than 45%. Subgroup analysis indicated that patients receiving dronedarone who had congestive heart failure had a benefit similar to that of the entire group. However, given the results of ANDROMEDA, dronedarone should not be initiated in patients with severe heart failure and left ventricular dysfunction.
Adverse events occurring significantly more frequently with dronedarone than with placebo included bradycardia, QT-interval prolongation, diarrhea, nausea, rash, and an increase in the serum creatinine level. The increase in creatinine level, which was also noted in ANDROMEDA, may not reflect a deterioration in renal function. Dronedarone reduces renal creatinine clearance by about 18%, without evidence of an effect on glomerular filtration rate, apparently as a result of a specific partial inhibition of tubular organic-cation transporters.17 Trial investigators were informed that a small rise in the creatinine level was expected with dronedarone and did not necessarily indicate a decline in renal function.
In this trial, no significant increase in the rates of thyroid or pulmonary disorders was seen with dronedarone. This observation may suggest that dronedarone has a more benign side-effect profile than amiodarone and that the intended benefits of the modifications in the benzofuran chemical structure were achieved. However, it is important to note that the mean follow-up for patients in the trial was only 21 months and that in many cases patients treated with amiodarone have such side effects (especially pulmonary toxic effects) later than 2 years after initiating therapy.
Another limitation of this trial is that the rate of premature discontinuation of the study drug was very high (30.2% in the dronedarone group). This may have resulted in an underestimate of the benefit of dronedarone, but it also may have limited the likelihood of demonstrating an increase in the rate of adverse events.
No antiarrhythmic agent other than dronedarone has been evaluated in a large trial involving patients with atrial fibrillation for the prevention of hospitalization due to cardiovascular events or death. Therefore, it is not possible to know the relative efficacy or safety of dronedarone as compared with other drugs for this outcome. The efficacy and tolerability of dronedarone and amiodarone as used to prevent the recurrence of atrial fibrillation are currently being evaluated in an ongoing randomized trial. In conclusion, among patients with atrial fibrillation, dronedarone was associated with a significant reduction in the rate of hospitalization due to cardiovascular events or death, as compared with placebo.
Supported by a grant from Sanofi-Aventis.
Dr. Hohnloser reports receiving consulting fees from Sanofi-Aventis, Cardiome, ARYx Therapeutics, and Bristol-Myers Squibb, research grants from Sanofi-Aventis and St. Jude Medical, and lecture fees from Sanofi-Aventis, St. Jude Medical, and Bristol-Myers Squibb; and Dr. Crijns, consulting fees from Medacorp, AstraZeneca, Sanofi-Aventis, and Cardiome, research grants from AstraZeneca and St. Jude Medical, and lecture fees from AstraZeneca, Sanofi-Aventis, and Chugai Pharmaceuticals. Dr. van Eickels and Dr. Gaudin report being employees of Sanofi-Aventis and owning shares in the company. Dr. Page reports receiving consulting fees from Sanofi-Aventis, Astellas, and Pfizer; Dr. Torp-Pedersen, consulting fees from Sanofi-Aventis and Cardiome, research grants from Sanofi-Aventis, and lecture fees from Sanofi-Aventis and Cardiome; and Dr. Connolly, consulting fees and research grants from Sanofi-Aventis. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0803778) was last updated on April 13, 2011, at NEJM.org.
Source Information
From the Department of Cardiology, J.W. Goethe University (S.H.H.), and Sanofi-Aventis (M.E., C.G.) — both in Frankfurt, Germany; Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands (H.J.G.M.C.); University of Washington, Seattle (R.L.P.); Gentofte Hospital, University of Copenhagen, Hellerup, Denmark (C.T.-P.); and McMaster University, Population Health Research Institute, Hamilton, ON, Canada (S.J.C.).
Address reprint requests to Dr. Hohnloser at the Division of Clinical Electrophysiology, J.W. Goethe University Hospital, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany, or at hohnloser@em.uni-frankfurt.de.
The investigators of ATHENA (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter) are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org.
- References
References
1
Go AS ,Hylek EM ,Philips KA , et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375
CrossRef | Web of Science | Medline2
Wattigney WA ,Mensah GA ,Croft JB . Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-716
CrossRef | Web of Science | Medline3
Calkins H ,Brugada J ,Packer DL , et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow up: a report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007;4:816-861
CrossRef | Web of Science | Medline4
Gautier P ,Marion A ,Bertrand JP ,Tourneur Y ,Nisato D . Electrophysiological characteristics of dronedarone (SR33589), a new amiodarone-like agent, in cardiac ventricular myocytes. Eur Heart J 1997;18:Suppl:269-2695
Sun W ,Sarma JS ,Singh BN . Electrophysiological effects of dronedarone (SR33589), a non-iodinated benzofuran derivative in the rabbit heart: comparison with amiodarone. Circulation 1999;100:2276-2281
Web of Science | Medline6
Sun W ,Sarma JS ,Singh BN . Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol 2002;39:677-684
CrossRef | Web of Science | Medline7
Wegener FT ,Ehrlich JR ,Hohnloser SH . Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol 2006;17:Suppl 2:S17-S20
CrossRef | Web of Science | Medline8
Zareba KM . Dronedarone: a new antiarrhythmic agent. Drugs Today (Barc) 2006;42:75-86
CrossRef | Web of Science | Medline9
Singh BN ,Connolly SJ ,Crijns HJ , et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007;357:987-999
Full Text | Web of Science | Medline10
Kober L ,Torp-Pedersen C ,McMurray JJV , et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 2008;358:2678-2687
Full Text | Web of Science | Medline11
Hohnloser SH ,Connolly SJ ,Crijns HJ ,Page RL ,Seiz W ,Torp-Pedersen C . Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. J Cardiovasc Electrophysiol 2008;19:69-73
CrossRef | Web of Science | Medline12
Hinkle LE Jr ,Thaler HT . Clinical classification of cardiac deaths. Circulation 1982;65:457-464
CrossRef | Web of Science | Medline13
Cairns JA ,Connolly SJ ,Roberts R ,Gent M . Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-682[Erratum, Lancet 1997;349:1776.]
CrossRef | Web of Science | Medline14
Connolly SJ ,Gent M ,Roberts RS , et al. Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297-1302
Web of Science | Medline15
Hohnloser SH ,Kuck KH ,Dorian P , et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004;351:2481-2488
Full Text | Web of Science | Medline16
Wyse DG ,Waldo AL ,DiMarco JP , et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833
Full Text | Web of Science | Medline17
Tschuppert Y ,Buclin T ,Rothuizen LE , et al. Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-791
Web of Science | Medline
- Citing Articles (236)
Citing Articles
1
A. John Camm, Christian F. Camm, Irina Savelieva. (2012) Medical treatment of atrial fibrillation. Journal of Cardiovascular Medicine 13:2, 97-107
CrossRef2
Athanasios J. Manolis, Enrico Agabiti Rosei, Antonio Coca, Renata Cifkova, Serap E. Erdine, Sverre Kjeldsen, Gregory Y.H. Lip, Krzysztof Narkiewicz, Gianfranco Parati, Josep Redon, Roland Schmieder, Costas Tsioufis, Giuseppe Mancia. (2012) Hypertension and atrial fibrillation. Journal of Hypertension 30:2, 239-252
CrossRef3
Jean-Marc Davy, François Roubille, Jean-Luc Pasquié. (2012) PALLAS: Insights into permanent atrial fibrillation. Archives of Cardiovascular Diseases
CrossRef4
Reginald Liew. (2012) Almanac 2011: Cardiac arrhythmias and pacing. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia (English Edition) 31:1, 57-69
CrossRef5
Jonas Bjerring Olesen, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Gregory Y. H. Lip. (2012) Atrial Fibrillation and Vascular Disease-A Bad Combination. Clinical Cardiology 35:S1, S15-S20
CrossRef6
Nihar R. Desai, Robert P. Giugliano. (2012) Can We Predict Outcomes in Atrial Fibrillation?. Clinical Cardiology 35:S1, S10-S14
CrossRef7
Yung Ly Kim, Boyoung Joung, Young Keun On, Chi Young Shim, Moon Hyoung Lee, Young-Hoon Kim, Hui-Nam Pak. (2012) Early Experience Using a Left Atrial Appendage Occlusion Device in Patients with Atrial Fibrillation. Yonsei Medical Journal 53:1, 83
CrossRef8
Reginald Liew. (2012) Almanac 2011: Cardiac arrhythmias and pacing. The national society journals present selected research that has driven recent advances in clinical cardiology. Revista Portuguesa de Cardiologia 31:1, 57-69
CrossRef9
Chern-En Chiang, Shu Zhang, Hung Fat Tse, Wee Siong Teo, Razali Omar, Charn Sriratanasathavorn. (2012) Atrial fibrillation management in Asia: From the Asian expert forum on atrial fibrillation. International Journal of Cardiology
CrossRef10
Manuel Anguita, Fernando Worner, Pere Domenech, Francisco Marín, Javier Ortigosa, Julián Pérez-Villacastín, Antonio Fernández-Ortiz, Angel Alonso, Angel Cequier, Josep Comín, Magda Heras, Manuel Pan, Javier Alzueta, Angel Arenal, Gonzalo Barón, Xavier Borrás, Ramón Bover, Mariano de la Figuera, Carlos Escobar, Miguel Fiol, Benito Herreros, José L. Merino, Lluis Mont, Nekane Murga, Alonso Pedrote, Aurelio Quesada, Tomás Ripoll, José Rodríguez, Martín Ruiz, Ricardo Ruiz. (2012) Nuevas evidencias, nuevas controversias: análisis crítico de la guía de práctica clínica sobre fibrilación auricular 2010 de la Sociedad Europea de Cardiología. Revista Española de Cardiología 65:1, 7-13
CrossRef11
Claire McKenna, Emma Maund, Muhammad Sarowar, David Fox, Matt Stevenson, Chris Pepper, Nerys Woolacott, Stephen Palmer. (2012) Dronedarone for the Treatment of Atrial Fibrillation. PharmacoEconomics 30:1, 35-46
CrossRef12
P. Kirchhof, G. Y. H. Lip, I. C. Van Gelder, J. Bax, E. Hylek, S. Kaab, U. Schotten, K. Wegscheider, G. Boriani, A. Brandes, M. Ezekowitz, H. Diener, L. Haegeli, H. Heidbuchel, D. Lane, L. Mont, S. Willems, P. Dorian, M. Aunes-Jansson, C. Blomstrom-Lundqvist, M. Borentain, S. Breitenstein, M. Brueckmann, N. Cater, A. Clemens, D. Dobrev, S. Dubner, N. G. Edvardsson, L. Friberg, A. Goette, M. Gulizia, R. Hatala, J. Horwood, L. Szumowski, L. Kappenberger, J. Kautzner, A. Leute, T. Lobban, R. Meyer, J. Millerhagen, J. Morgan, F. Muenzel, M. Nabauer, C. Baertels, M. Oeff, D. Paar, J. Polifka, U. Ravens, L. Rosin, W. Stegink, G. Steinbeck, P. Vardas, A. Vincent, M. Walter, G. Breithardt, A. J. Camm. (2012) Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 14:1, 8-27
CrossRef13
Stefan H. Hohnloser. (2012) Benefit-Risk Assessment of Current Antiarrhythmic Drug Therapy of Atrial Fibrillation. Clinical Cardiology 35:S1, S28-S32
CrossRef14
Manuel Anguita, Fernando Worner, Pere Domenech, Francisco Marín, Javier Ortigosa, Julián Pérez-Villacastín, Antonio Fernández-Ortiz, Angel Alonso, Angel Cequier, Josep Comín, Magda Heras, Manuel Pan, Javier Alzueta, Angel Arenal, Gonzalo Barón, Xavier Borrás, Ramón Bover, Mariano de la Figuera, Carlos Escobar, Miguel Fiol, Benito Herreros, José L. Merino, Lluis Mont, Nekane Murga, Alonso Pedrote, Aurelio Quesada, Tomás Ripoll, José Rodríguez, Martín Ruiz, Ricardo Ruiz. (2012) New Evidence, New Controversies: a Critical Review of the European Society of Cardiology 2010 Clinical Practice Guidelines on Atrial Fibrillation. Revista Española de Cardiología (English Edition) 65:1, 7-13
CrossRef15
M. Gosch, R.E. Roller, B. Böhmdorfer, U. Benvenuti-Falger, B. Iglseder, M. Lechleitner, U. Sommeregger, P. Dovjak. (2012) Management und Therapie des Vorhofflimmerns beim geriatrischen Patienten. Zeitschrift für Gerontologie und Geriatrie 45:1, 55-68
CrossRef16
, Michael D. Ezekowitz, Rangadham Nagarakanti, Andrzej Lubinski, Olga Bandman, Daniel Canafax, David J. Ellis, Peter G. Milner, Margaret Ziola, Bernard Thibault, Stefan H. Hohnloser. (2011) A randomized trial of budiodarone in paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology
CrossRef17
Connolly, Stuart J., Camm, A. John, Halperin, Jonathan L., Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B., Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S., Merino, Jose L., Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S., Sim, Kui-Hian, Stiles, Martin K., Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, Hohnloser, Stefan H., . (2011) Dronedarone in High-Risk Permanent Atrial Fibrillation. New England Journal of Medicine 365:24, 2268-2276
Full Text18
Nattel, Stanley, . (2011) Dronedarone in Atrial Fibrillation — Jekyll and Hyde?. New England Journal of Medicine 365:24, 2321-2322
Full Text19
Gregory YH Lip, Hung Fat Tse, Deirdre A Lane. (2011) Atrial fibrillation. The Lancet
CrossRef20
Marc Cohen, Catalin Boiangiu. (2011) The Management of Patients with Atrial Fibrillation and Dronedarone’s Place in Therapy. Advances in Therapy 28:12, 1059-1077
CrossRef21
AVINASH R. KHITRI, ETIENNE M. ALIOT, ALESSANDRO CAPUCCI, STUART J. CONNOLLY, HARRY CRIJNS, STEFAN H. HOHNLOSER, PIOTR KULAKOWSKI, DENIS ROY, DAVID RADZIK, PETER R. KOWEY. (2011) Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter. Journal of Cardiovascular Electrophysiologyno-no
CrossRef22
Nikolaos Dagres, Christos Varounis, Efstathios K. Iliodromitis, John P. Lekakis, Loukianos S. Rallidis, Maria Anastasiou-Nana. (2011) Dronedarone and the Incidence of Stroke in Patients with Paroxysmal or Persistent Atrial Fibrillation. American Journal Cardiovascular Drugs 11:6, 395-400
CrossRef23
Girish M. Nair, Jeffrey S. Healey, Syamkumar M. Divakaramenon, Stuart J. Connolly, Carlos A. Morillo. (2011) Antiarrhythmic Drug Therapy for New-Onset Ventricular Arrhythmia (VT/VF) in ICD Patients. Cardiac Electrophysiology Clinics 3:4, 651-661
CrossRef24
Alena Shantsila, Gregory Y.H. Lip. (2011) Dronedarone. American Journal Cardiovascular Drugs 11:6, 355-356
CrossRef25
T. Deneke, T. Lawo, J. Reinecke, C. Buttler, P.H. Grewe, D.-I. Shin, B. Gerritse, A. Mügge, B. Lemke, A. Kloppe. (2011) Predictors of sustained ventricular arrhythmia episodes in patients with primary ICD indication. Herzschrittmachertherapie + Elektrophysiologie 22:4, 219-225
CrossRef26
Pedram Kazemian, Gavin Oudit, Bodh I. Jugdutt. (2011) Atrial fibrillation and heart failure in the elderly. Heart Failure Reviews
CrossRef27
Steven M. Markowitz. (2011) Rhythm Control for Atrial Fibrillation. Journal of the American College of Cardiology 58:19, 1986-1988
CrossRef28
Nicole C Silvester, Christopher H George. (2011) Searching for new cardiovascular drugs: towards improved systems for drug screening?. Expert Opinion on Drug Discovery 6:11, 1155-1170
CrossRef29
Nadzeya Kuzniatsova, Burak Pamukcu, Gregory YH Lip. (2011) Dronedarone (Multaq ® ) for the treatment of atrial fibrillation. Therapy 8:6, 681-689
CrossRef30
Sanjeev Saksena, April Slee, Albert L. Waldo, Nick Freemantle, Mathew Reynolds, Yves Rosenberg, Snehal Rathod, Shannon Grant, Elizabeth Thomas, D. George Wyse. (2011) Cardiovascular Outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). Journal of the American College of Cardiology 58:19, 1975-1985
CrossRef31
I. C. Van Gelder, L. M. Haegeli, A. Brandes, H. Heidbuchel, E. Aliot, J. Kautzner, L. Szumowski, L. Mont, J. Morgan, S. Willems, S. Themistoclakis, M. Gulizia, A. Elvan, M. D. Smit, P. Kirchhof. (2011) Rationale and current perspective for early rhythm control therapy in atrial fibrillation. Europace 13:11, 1517-1525
CrossRef32
Melinda J. Carrington, Jocasta Ball, John D. Horowitz, Thomas H. Marwick, Gnanadevan Mahadevan, Chiew Wong, Walter P. Abhayaratna, Brian Haluska, David R. Thompson, Paul A. Scuffham, Simon Stewart. (2011) Navigating the fine line between benefit and risk in chronic atrial fibrillation: Rationale and design of the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). International Journal of Cardiology
CrossRef33
J. H. Park, B. Joung, N.-H. Son, J. M. Shim, M. H. Lee, C. Hwang, H.-N. Pak. (2011) The electroanatomical remodelling of the left atrium is related to CHADS2/CHA2DS2VASc score and events of stroke in patients with atrial fibrillation. Europace 13:11, 1541-1549
CrossRef34
Cen Xie, Shilei Yang, Dafang Zhong, Xiaojian Dai, Xiaoyan Chen. (2011) Simultaneous determination of dronedarone and its active metabolite debutyldronedarone in human plasma by liquid chromatography–tandem mass spectrometry: Application to a pharmacokinetic study. Journal of Chromatography B 879:28, 3071-3075
CrossRef35
K. Wasmer, L. Eckardt. (2011) Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace 13:10, 1368-1374
CrossRef36
Jonathan P. Piccini, Elizabeth S. Fraulo, Jack E. Ansell, Gregg C. Fonarow, Bernard J. Gersh, Alan S. Go, Elaine M. Hylek, Peter R. Kowey, Kenneth W. Mahaffey, Laine E. Thomas, Melissa H. Kong, Renato D. Lopes, Roger M. Mills, Eric D. Peterson. (2011) Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF. American Heart Journal 162:4, 606-612.e1
CrossRef37
Jonathan Buber, Michael Glikson, Michael Eldar, David Luria. (2011) Exercise Heart Rate Acceleration Patterns during Atrial Fibrillation and Sinus Rhythm. Annals of Noninvasive Electrocardiology 16:4, 357-364
CrossRef38
, Thomas Meinertz, Wilhelm Kirch, Ludger Rosin, David Pittrow, Stefan N. Willich, Paulus Kirchhof. (2011) Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry. Clinical Research in Cardiology 100:10, 897-905
CrossRef39
Jen-Hung Huang, Yung-Kuo Lin, Ming-Hsiung Hsieh, Shih-Ann Chen, Yi-Jen Chen. (2011) Thyroxine monotherapy without amiodarone enhances atrial fibrillation recurrences in amiodarone-induced hypothyroidism. International Journal of Cardiology 152:2, 277-278
CrossRef40
Daniel Caldeira, Cláudio David, Cristina Sampaio. (2011) Rate vs rhythm control in patients with atrial fibrillation and heart failure: A systematic review and meta-analysis of randomised controlled trials. European Journal of Internal Medicine 22:5, 448-455
CrossRef41
Alpesh N. Amin, Mehul Jhaveri, Jay Lin. (2011) Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Advances in Therapy 28:10, 907-926
CrossRef42
Gregory M. Marcus, Melvin M. Scheinman, Edmund Keung. (2011) The Year in Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology 58:16, 1645-1655
CrossRef43
Shinsuke Miyazaki, Ashok J. Shah, Daniel Scherr, Michel Haïssaguerre. (2011) Atrial fibrillation: Pathophysiology and current therapy. Annals of Medicine 43:6, 425-436
CrossRef44
Jason Bradfield, Roderick Tung, Noel G. Boyle, Kalyanam Shivkumar. (2011) Managing patients with ICD shocks and programming tachycardia therapies during acute heart failure syndromes. Heart Failure Reviews 16:5, 449-456
CrossRef45
D. Petrač. (2011) Antiarrhythmic drugs for maintaining of sinus rhythm. Interventional Medicine and Applied Science 3:3, 116-119
CrossRef46
B. Lüderitz. (2011) History of atrial fibrillation. Interventional Medicine and Applied Science 3:3, 138-141
CrossRef47
B. Fuentes, J. Gállego, A. Gil-Nuñez, A. Morales, F. Purroy, J. Roquer, T. Segura, J. Tejada, A. Lago, E. Díez-Tejedor, M. Alonso de Leciñana, J. Álvarez-Sabin, J. Arenillas, S. Calleja, I. Casado, M. Castellanos, J. Castillo, A. Dávalos, F. Díaz-Otero, J.A. Egido, J.C. López-Fernández, M. Freijo, A. García Pastor, F. Gilo, P. Irimia, J. Maestre, J. Masjuan, J. Martí-Fábregas, P. Martínez-Sánchez, E. Martínez-Vila, C. Molina, F. Nombela, M. Ribó, M. Rodríguez-Yañez, F. Rubio, J. Serena, P. Simal, J. Vivancos. (2011) Guía para el tratamiento preventivo del ictus isquémico y AIT (II). Recomendaciones según subtipo etiológico. Neurología
CrossRef48
Shujun Gao, Juhaeri Juhaeri, Heather A. Schiappacasse, Andrew T. Koren, Wanju S. Dai. (2011) Evaluation of Dronedarone Use in the US Patient Population Between 2009 and 2010: A Descriptive Study Using a Claims Database. Clinical Therapeutics
CrossRef49
I. Savelieva, P. Kirchhof, N. Danchin, P. A. de Graeff, A. J. Camm. (2011) Regulatory pathways for development of antiarrhythmic drugs for management of atrial fibrillation/flutter. Europace 13:8, 1063-1076
CrossRef50
C. Torp-Pedersen, H. J. G. M. Crijns, C. Gaudin, R. L. Page, S. J. Connolly, S. H. Hohnloser, . (2011) Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. Europace 13:8, 1118-1126
CrossRef51
Joachim R. Ehrlich, Dobromir Dobrev. (2011) Atrial-selective sodium channel block by dronedarone: sufficient to terminate atrial fibrillation?. Naunyn-Schmiedeberg's Archives of Pharmacology 384:2, 109-114
CrossRef52
T. JARED BUNCH, BRIAN G. CRANDALL, J. PETER WEISS, HEIDI T. MAY, TAMI L. BAIR, JEFFREY S. OSBORN, JEFFREY L. ANDERSON, JOSEPH B. MUHLESTEIN, BENJAMIN D. HORNE, DONALD L. LAPPE, JOHN D. DAY. (2011) Patients Treated with Catheter Ablation for Atrial Fibrillation Have Long-Term Rates of Death, Stroke, and Dementia Similar to Patients Without Atrial Fibrillation. Journal of Cardiovascular Electrophysiology 22:8, 839-845
CrossRef53
Charles Antzelevitch, Alexander Burashnikov, Serge Sicouri, Luiz Belardinelli. (2011) Electrophysiologic basis for the antiarrhythmic actions of ranolazine. Heart Rhythm 8:8, 1281-1290
CrossRef54
J. Y. Le Heuzey. (2011) Hospitalization: a relevant endpoint in atrial fibrillation management?. Europace 13:8, 1061-1062
CrossRef55
J.L. Llisterri Caro, J. Polo García, J.C. Martí Canales, V. Barrios Alonso. (2011) Nuevas estrategias terapéuticas para la prevención del ictus en pacientes con fibrilación auricular: perspectiva desde atención primaria. SEMERGEN - Medicina de Familia 37:7, 352-359
CrossRef56
H.J. Audebert. (2011) Schlaganfallbehandlung 2011. Notfall + Rettungsmedizin 14:5, 413-424
CrossRef57
Vera H.M. Deneer, Norbert M. van Hemel. (2011) Is Antiarrhythmic Treatment in the Elderly Different?. Drugs & Aging 28:8, 617-633
CrossRef58
Dariusz Kozlowski, Szymon Budrejko, Gregory Y. H. Lip, Dimitri P. Mikhailidis, Jacek Rysz, Grzegorz Raczak, Maciej Banach. (2011) Dronedarone: An overview. Annals of Medicine1-13
CrossRef59
Mark A. Kotowycz, Kristian B. Filion, Jacqueline Joza, Doris Dube, Matthew R. Reynolds, Louise Pilote, Mark J. Eisenberg, Vidal Essebag. (2011) In-Hospital Management of Atrial Fibrillation: The CHADS2 Score Predicts Increased Cost. Canadian Journal of Cardiology 27:4, 506-513
CrossRef60
A. John Camm, Günter Breithardt, Harry Crijns, Paul Dorian, Peter Kowey, Jean-Yves Le Heuzey, Ihsen Merioua, Laurence Pedrazzini, Eric N. Prystowsky, Peter J. Schwartz, Christian Torp-Pedersen, William Weintraub. (2011) Real-Life Observations of Clinical Outcomes With Rhythm- and Rate-Control Therapies for Atrial Fibrillation. Journal of the American College of Cardiology 58:5, 493-501
CrossRef61
GABOR Z. DURAY, CHRISTIAN TORP-PEDERSEN, STUART J. CONNOLLY, STEFAN H. HOHNLOSER. (2011) Effects of Dronedarone on Clinical Outcomes in Patients with Lone Atrial Fibrillation: Pooled Post Hoc Analysis from the ATHENA/EURIDIS/ADONIS Studies. Journal of Cardiovascular Electrophysiology 22:7, 770-776
CrossRef62
ANDREA M. RUSSO. (2011) The Impact of Dronedarone on Lone Atrial Fibrillation: Perhaps Not Such a “Benign” Arrhythmia?. Journal of Cardiovascular Electrophysiology 22:7, 777-780
CrossRef63
Eric TS Lim, Jonathan Yap, Chee Tang Chin. (2011) Current and emerging therapies for stroke prophylaxis in atrial fibrillation. Clinical Investigation 1:7, 1019-1037
CrossRef64
Andreas Skyschally, Gerd Heusch. (2011) Reduction of Myocardial Infarct Size by Dronedarone in Pigs—A Pleiotropic Action?. Cardiovascular Drugs and Therapy 25:3, 197-201
CrossRef65
Alexandra Perez, Daniel R Touchette, Robert J DiDomenico, Thomas D Stamos, Surrey M Walton. (2011) Comparison of Rate Control versus Rhythm Control for Management of Atrial Fibrillation in Patients with Coexisting Heart Failure: A Cost-Effectiveness Analysis. Pharmacotherapy 31:6, 552-565
CrossRef66
Nikolaos Dagres, Philipp Sommer, Maria Anastasiou-Nana, Gerhard Hindricks. (2011) Treating arrhythmias: an expert opinion. Expert Opinion on Pharmacotherapy 12:9, 1359-1367
CrossRef67
Michele Marzocchi, Federico Lombardi. (2011) Dronedarone for atrial fibrillation therapy. Expert Review of Cardiovascular Therapy 9:6, 675-683
CrossRef68
Gerald V. Naccarelli. (2011) Post-ATHENA and beyond. Journal of Interventional Cardiac Electrophysiology 31:1, 55-60
CrossRef69
Paul Dorian. (2011) “Show Me the Money”: The Cost of Atrial Fibrillation. Canadian Journal of Cardiology
CrossRef70
John Camm. (2011) Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits. International Journal of Cardiology
CrossRef71
Dobromir Dobrev. (2011) Prevention of atrial fibrillation complications with antiarrhythmic drugs: still an unmet need in clinical practice. Expert Opinion on Pharmacotherapy 12:8, 1195-1199
CrossRef72
Alessandro Marinelli, Alessandro Capucci. (2011) Antiarrhythmic drugs for atrial fibrillation. Expert Opinion on Pharmacotherapy 12:8, 1201-1215
CrossRef73
T. Jared Bunch, Bernard J. Gersh. (2011) Rhythm Control Strategies and the Role of Antiarrhythmic Drugs in the Management of Atrial Fibrillation: Focus on Clinical Outcomes. Journal of General Internal Medicine 26:5, 531-537
CrossRef74
Laurent M Haegeli, Firat Duru. (2011) Atrial fibrillation in the aging heart: pharmacological therapy and catheter ablation in the elderly. Future Cardiology 7:3, 415-423
CrossRef75
Luisa Benito, Jordi Hoyo, Àngels Montroig, Berta Fornés, Guillem Fluxà, David Martí, Montserrat Pedrós, Antoni Sisó, Lluís Mont, Òscar Miró, Blanca Coll-Vinent. (2011) Estudio sobre los efectos adversos de los fármacos antiarrítmicos en pacientes con fibrilación auricular atendidos en un Centro de Atención Primaria. Medicina Clínica
CrossRef76
L. Friberg, M. Rosenqvist. (2011) Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 13:5, 626-633
CrossRef77
Sony Jacob, Omaima A Ali, Victoria Pidlaoan, Apurva O Badheka, Nicholas Z Kerin. (2011) Pharmacotherapy of Atrial Fibrillation: A Pathophysiological Perspective and Review. American Journal of Therapeutics 18:3, 241-260
CrossRef78
R. Nieuwlaat. (2011) The value of cardiovascular hospitalization as an endpoint for clinical atrial fibrillation research. Europace 13:5, 601-602
CrossRef79
Hendrik Bonnemeier, Ralph F. Bosch, Annette Kohlhaußen, Ludger Rosin, Stefan N. Willich, David Pittrow, Wilhelm Kirch, for the MOVE Study Group. (2011) Presentation of atrial fibrillation and its management by cardiologists in the ambulatory and hospital setting: MOVE cross-sectional study. Current Medical Research and Opinion 27:5, 995-1003
CrossRef80
C. Blomstrom Lundqvist, G. Y. H. Lip, P. Kirchhof. (2011) What are the costs of atrial fibrillation?. Europace 13:Supplement 2, ii9-ii12
CrossRef81
2011. Active Supraventricular Arrhythmias. , 93-180.
CrossRef82
2011. Appendix. , 386-418.
CrossRef83
2011. Active Ventricular Arrhythmias. , 181-229.
CrossRef84
Roman Bogdan, Heinz Goegelein, Hartmut Ruetten. (2011) Effect of dronedarone on Na+, Ca2+ and HCN channels. Naunyn-Schmiedeberg's Archives of Pharmacology 383:4, 347-356
CrossRef85
Richard L. Page, Stuart J. Connolly, Harry J.G.M. Crijns, Martin van Eickels, Christophe Gaudin, Christian Torp-Pedersen, Stefan H. Hohnloser. (2011) Rhythm- and Rate-Controlling Effects of Dronedarone in Patients With Atrial Fibrillation (from the ATHENA Trial). The American Journal of Cardiology 107:7, 1019-1022
CrossRef86
T. S. Potpara, G. Y. H. Lip. (2011) Lone atrial fibrillation: what is known and what is to come. International Journal of Clinical Practice 65:4, 446-457
CrossRef87
Melissa R. Robinson, Andrew E. Epstein, David J. Callans. (2011) Secondary Prevention in Heart Failure. Heart Failure Clinics 7:2, 185-194
CrossRef88
Edward L. Korn, Boris Freidlin. (2011) Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report. The American Journal of Bioethics 11:3, 2-10
CrossRef89
David Filgueiras Rama, José Jalife. (2011) Mechanisms Underlying Atrial Fibrillation. Cardiac Electrophysiology Clinics 3:1, 141-156
CrossRef90
Alexander Burashnikov, Charles Antzelevitch. (2011) Advances in the Pharmacologic Management of Atrial Fibrillation. Cardiac Electrophysiology Clinics 3:1, 157-167
CrossRef91
Saurabh Malhotra, Mithilesh K Das. (2011) Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death. Future Cardiology 7:2, 203-217
CrossRef92
N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds. (2011) Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace 13:3, 329-345
CrossRef93
D. M. Leistner, J. Schmitt, S. Palm, J. Klotsche, S. Estel, A. Fink, C. W. Israel, B. Assmus, G. Z. Duray, S. Dimmeler, S. H. Hohnloser, A. M. Zeiher. (2011) Intracoronary administration of bone marrow-derived mononuclear cells and arrhythmic events in patients with chronic heart failure. European Heart Journal 32:4, 485-491
CrossRef94
Simerpreet Bal, Pawan Ojha, Michael D. Hill. (2011) Stroke Prevention Treatment of Patients with Atrial Fibrillation: Old and New. Current Neurology and Neuroscience Reports 11:1, 15-27
CrossRef95
Michael Broukhim, Jonathan L. Halperin. (2011) Stroke Prevention in the High-risk Atrial Fibrillation Patient: Medical Management. Current Cardiology Reports 13:1, 9-17
CrossRef96
A. Fink, G. Z. Duray, S. H. Hohnloser. (2011) A patient with recurrent atrial fibrillation and monomorphic ventricular tachycardia treated successfully with dronedarone. Europace 13:2, 284-285
CrossRef97
J. Röther. (2011) Epidemiologie, Klinik und Management des Vorhofflimmerns. Der Nervenarzt 82:2, 159-165
CrossRef98
Pasquale Santangeli, Luigi Di Biase, Gemma Pelargonio, J. David Burkhardt, Andrea Natale. (2011) The pharmaceutical pipeline for atrial fibrillation. Annals of Medicine 43:1, 13-32
CrossRef99
JAMES A. REIFFEL. (2011) Atrial Fibrillation: What Have Recent Trials Taught Us Regarding Pharmacologic Management of Rate and Rhythm Control?. Pacing and Clinical Electrophysiology 34:2, 247-259
CrossRef100
Stuart J. Connolly. (2011) Atrial fibrillation in 2010: Advances in treatment and management. Nature Reviews Cardiology 8:2, 67-68
CrossRef101
T. Barry Levine, Thomas Giles, David Radzik, Jalal K. Ghali. (2011) Effect of Dronedarone on Exercise Capacity and Cardiac Function in Patients With Severe Left Ventricular Dysfunction and Compensated Stable Heart Failure. Cardiovascular Drugs and Therapy
CrossRef102
Eric S Williams, Burr Hall, Darren Traub, Tristram Bahnson, Patrick Hranitzky, Wojciech Zareba, James P Daubert. (2011) Catheter ablation of atrial fibrillation in the elderly. Current Opinion in Cardiology 26:1, 25-29
CrossRef103
L. Samuel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman, William G. Stevenson, Cynthia M. Tracy, Valentin Fuster, Lars E. Rydén, David S. Cannom, Jean-Yves Le Heuzey, Harry J. Crijns, James E. Lowe, Anne B. Curtis, S. Bertil Olsson, Kenneth A. Ellenbogen, Eric N. Prystowsky, Jonathan L. Halperin, Juan Luis Tamargo, G. Neal Kay, L. Samuel Wann. (2011) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Journal of the American College of Cardiology 57:2, 223-242
CrossRef104
Walid Saliba, Oussama M. Wazni. (2011) Sinus Rhythm Restoration and Treatment Success: Insight From Recent Clinical Trials. Clinical Cardiology 34:1, 12-22
CrossRef105
Juan F. Viles-Gonzalez, Valentin Fuster, Jonathan Halperin, Hugh Calkins, Vivek Y. Reddy. (2011) Rhythm Control for Management of Patients With Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation. Clinical Cardiology 34:1, 23-29
CrossRef106
Laurent M. Haegeli, Firat Duru. (2011) Management of Patients with Atrial Fibrillation: Specific Considerations for the Old Age. Cardiology Research and Practice 2011, 1-8
CrossRef107
Xavier Borrás-Pérez, Nekane Murga-Eizagaechevarría. (2011) Novedades en cardiología clínica. La actitud del cardiólogo clínico ante los nuevos fármacos cardiovasculares. Revista Española de Cardiología 64, 73-80
CrossRef108
Masaomi Chinushi, Kenichi Iijima. (2011) Rate Control Is a Better Initial Treatment for Patients With Atrial Fibrillation and Heart Failure. Circulation Journal 75:4, 970-978
CrossRef109
Antonio Hernández-Madrid, Roberto Matía Francés, Concepción Moro. (2011) Novedades en electrofisiología cardiaca y arritmias. Revista Española de Cardiología 64, 81-90
CrossRef110
A. Finzi. 2011. Positive inotropic drugs and drugs used in dysrhythmias. , 377-395.
CrossRef111
Fabiana Lucà, Mark La Meir, Carmelo Massimiliano Rao, Orlando Parise, Ludovico Vasquez, Rocco Carella, Roberto Lorusso, Benedetto Daniela, Jos Maessen, Gian Franco Gensini, Sandro Gelsomino. (2011) Pharmacological Management of Atrial Fibrillation: One, None, One Hundred Thousand. Cardiology Research and Practice 2011, 1-10
CrossRef112
Yaariv Khaykin, Yana Shamiss. (2011) Cost of AF Ablation: Where Do We Stand?. Cardiology Research and Practice 2011, 1-6
CrossRef113
G. Ntaios, P. Michel. (2011) Temporal Distribution and Magnitude of the Vulnerability Period around Stroke Depend on Stroke Subtype. Cerebrovascular Diseases 32:3, 246-253
CrossRef114
Haruaki Nakaya. (2011) Novel Antiarrhythmic Drugs for the Treatment of Atrial Fibrillation: Current Perspective. Journal of Arrhythmia 27:2, 156-157
CrossRef115
Michelle D Schmiegelow, Ole D Pedersen, Lars Køber, Marie Seibæk, Steen Z Abildstrøm, Christian Torp-Pedersen. (2011) Incidence of Atrial Fibrillation in Patients with either Heart Failure or Acute Myocardial Infarction and Left Ventricular Dysfunction: A Cohort Study. BMC Cardiovascular Disorders 11:1, 19
CrossRef116
L. Samuel Wann, Anne B. Curtis, Craig T. January, Kenneth A. Ellenbogen, James E. Lowe, N.A. Mark Estes, Richard L. Page, Michael D. Ezekowitz, David J. Slotwiner, Warren M. Jackman, William G. Stevenson, Cynthia M. Tracy. (2011) 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). Heart Rhythm 8:1, 157-176
CrossRef117
Razali Omar, Wee Siong Teo, David Foo, Chee Kok Han, Ahmad Nizar Jamaluddin, Lip Ping Low, Tiong Kiam Ong. (2011) Atrial Fibrillation in Singapore and Malaysia: Current Trends and Future Prospects. Journal of Arrhythmia 27:3, 171-185
CrossRef118
Sylvia Abadir, Paul Khairy. (2011) Electrophysiology and Adult Congenital Heart Disease: Advances and Options. Progress in Cardiovascular Diseases 53:4, 281-292
CrossRef119
Y Z Xue, L X Wang. (2010) Contemporary management of atrial fibrillation: a brief review. Advances in Medical Sciences 55:2, 130-136
CrossRef120
B.-D. Gonska. (2010) Dronedaron. Herzschrittmachertherapie + Elektrophysiologie 21:4, 244-247
CrossRef121
J.-Y. Le Heuzey. (2010) Prise en charge de la fibrillation atriale, ce qu’il faut savoir sur les anciens et les nouveaux anti-arythmiques. Annales de Cardiologie et d'Angéiologie 59, S24-S27
CrossRef122
A. Leenhardt, G. Moubarak, A. Messali, F. Extramiana. (2010) La fibrillation atriale est-elle un marqueur indépendant de risque cardio-vasculaire ?. Annales de Cardiologie et d'Angéiologie 59, S14-S18
CrossRef123
S. Kacet. (2010) Thérapeutiques actuelles de la fibrillation atriale, rythme et fréquence, réflexion sur un nouveau paradigme de prise en charge. Annales de Cardiologie et d'Angéiologie 59, S33-S36
CrossRef124
H. Simon, K. Simon Demel, G. Ritscher, O. Turschner, J. Brachmann. (2010) Neue Entwicklungen in der antiarrhythmischen Therapie des Vorhofflimmerns. Herzschrittmachertherapie + Elektrophysiologie 21:4, 212-216
CrossRef125
Martin Schwaiblmair, Thomas Berghaus, Thomas Haeckel, Theodor Wagner, Wolfgang Scheidt. (2010) Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?. Clinical Research in Cardiology 99:11, 693-700
CrossRef126
Mark D. O'Neill, Matthew Wright, Pierre Jaïs, Sebastien Knecht, Isabelle Nault, Seiichiro Matsuo, Shinsuke Miyazaki, Andrej Pernat, Amir Jadidi, Frédéric Sacher, D. Wyn Davies, Jacques Clémenty, Michel Haïssaguerre, Mélèze Hocini. 2010. Treatment of Atrial Arrhythmias in Heart Failure Patients. , 217-234.
CrossRef127
Stuart J. Connolly, Stefan H. Hohnloser. (2010) Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 56:16, 1353-1354
CrossRef128
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal 31:19, 2369-2429
CrossRef129
Alexander Burashnikov, Serge Sicouri, José M. Di Diego, Luiz Belardinelli, Charles Antzelevitch. (2010) Synergistic Effect of the Combination of Ranolazine and Dronedarone to Suppress Atrial Fibrillation. Journal of the American College of Cardiology 56:15, 1216-1224
CrossRef130
Mark Alber Meshil, Deepak Bhakta. (2010) REVIEW: Nonpharmacological Therapies for Atrial Fibrillation. Cardiovascular Therapeutics 28:5, 264-277
CrossRef131
, , , A. J. Camm, P. Kirchhof, G. Y. H. Lip, U. Schotten, I. Savelieva, S. Ernst, I. C. Van Gelder, N. Al-Attar, G. Hindricks, B. Prendergast, H. Heidbuchel, O. Alfieri, A. Angelini, D. Atar, P. Colonna, R. De Caterina, J. De Sutter, A. Goette, B. Gorenek, M. Heldal, S. H. Hohloser, P. Kolh, J.-Y. Le Heuzey, P. Ponikowski, F. H. Rutten, , A. Vahanian, A. Auricchio, J. Bax, C. Ceconi, V. Dean, G. Filippatos, C. Funck-Brentano, R. Hobbs, P. Kearney, T. McDonagh, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, P. E. Vardas, P. Widimsky, , P. E. Vardas, V. Agladze, E. Aliot, T. Balabanski, C. Blomstrom-Lundqvist, A. Capucci, H. Crijns, B. Dahlof, T. Folliguet, M. Glikson, M. Goethals, D. C. Gulba, S. Y. Ho, R. J. M. Klautz, S. Kose, J. McMurray, P. Perrone Filardi, P. Raatikainen, M. J. Salvador, M. J. Schalij, A. Shpektor, J. Sousa, J. Stepinska, H. Uuetoa, J. L. Zamorano, I. Zupan. (2010) Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12:10, 1360-1420
CrossRef132
Arnold Pinter, Paul Dorian. (2010) REVIEW: New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. Cardiovascular Therapeutics 28:5, 302-310
CrossRef133
Shailesh C. Shirolkar, Mona Fiuzat, Richard C. Becker. (2010) Dronedarone and vitamin K antagonists: A review of drug-drug interactions. American Heart Journal 160:4, 577-582
CrossRef134
Ralph Weber, Hans-Christoph Diener, Christian Weimar. (2010) Prevention of cardioembolic stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 8:10, 1405-1415
CrossRef135
David Singh, Eugenio Cingolani, George A. Diamond, Sanjay Kaul. (2010) Reply. Journal of the American College of Cardiology 56:16, 1354-1355
CrossRef136
Jason T. Jacobson, Justin B. Weiner. (2010) REVIEW: Management of Ventricular Tachycardia in Patients with Structural Heart Disease. Cardiovascular Therapeutics 28:5, 255-263
CrossRef137
Peter J. Hughes, Maisha Kelly Freeman, Frances V. Cohenour, Emily M. Price. (2010) Dronedarone: An Alternative to Amiodarone?. The Consultant Pharmacist 25:9, 555-569
CrossRef138
F. Marín, G. Y. H. Lip. (2010) Rhythm control agents and adverse events in patients with atrial fibrillation. International Journal of Clinical Practice 64:10, 1329-1331
CrossRef139
A. Gil Núñez. (2010) Avances en la prevención de la isquemia cerebral por fibrilación auricular. Neurología 25:7, 401-408
CrossRef140
Alexander Burashnikov, Luiz Belardinelli, Charles Antzelevitch. (2010) Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria. Heart Rhythm 7:9, 1273-1279
CrossRef141
Daniel E Hilleman, Aryan N Mooss. (2010) Role of Dronedarone in Atrial Fibrillation: More Questions Than Answers. Pharmacotherapy 30:9, 867-871
CrossRef142
Ola O Oyetayo, Carrie E Rogers, Prudence O Hofmann. (2010) Dronedarone: A New Antiarrhythmic Agent. Pharmacotherapy 30:9, 904-915
CrossRef143
P. Aguiar-Souto, S. Raposeiras-Roubín, J.R. González-Juanatey. (2010) Novedades en el último año en el planteamiento terapéutico de la cardiopatía hipertensiva, de la cardiopatía isquémica y de la fibrilación auricular. Revista Clínica Española 210, 2-11
CrossRef144
Andrew J. Krainik, Jane Chen. (2010) Atrial Fibrillation in the Elderly. Current Cardiovascular Risk Reports 4:5, 354-360
CrossRef145
Michael R. Franz, Steve N. Singh. (2010) Amiodarone and dronedarone: The worker bee and the drone?. Heart Rhythm 7:9, 1280-1281
CrossRef146
Leif Carlsson, Göran Duker, Ingemar Jacobson. (2010) New pharmacological targets and treatments for atrial fibrillation. Trends in Pharmacological Sciences 31:8, 364-371
CrossRef147
Chee W Khoo, Hoong Sern Lim, Gregory YH Lip. (2010) Dronedarone: NICE enough?. Expert Review of Cardiovascular Therapy 8:8, 1049-1051
CrossRef148
Gregory M. Marcus, Melvin M. Scheinman, Edmund Keung. (2010) The Year in Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology 56:8, 667-676
CrossRef149
M. Stramba-Badiale. (2010) Women and research on cardiovascular diseases in Europe: a report from the European Heart Health Strategy (EuroHeart) project. European Heart Journal 31:14, 1677-1681
CrossRef150
S. H. Hohnloser, H. J. G. M. Crijns, M. van Eickels, C. Gaudin, R. L. Page, C. Torp-Pedersen, S. J. Connolly, . (2010) Dronedarone in patients with congestive heart failure: insights from ATHENA. European Heart Journal 31:14, 1717-1721
CrossRef151
Angela L McClanahan, Anne B Curtis. (2010) Rate versus rhythm control in atrial fibrillation: no one-size-fits-all. Expert Review of Cardiovascular Therapy 8:7, 891-893
CrossRef152
Alessandro Marinelli, Alessandro Rosi, Alessandro Capucci. (2010) Role of sotalol in rhythm control of atrial fibrillation. Therapy 7:4, 391-407
CrossRef153
MUSTAPHASAHIM SHAARAOUI, RONALD FREUDENBERGER, VADIM LEVIN, FRANCIS E. MARCHLINSKI. (2010) Suppression of Ventricular Tachycardia With Dronedarone: A Case Report. Journal of Cardiovascular Electrophysiologyno-no
CrossRef154
Fikret Er, Orhan Aslan, Evren Caglayan, Natig Gassanov, Amir M. Nia, Erland Erdmann, Stephan Rosenkranz. (2010) Flecainide for cardioversion in patients at elevated cardiovascular risk and persistent atrial fibrillation: a prospective observational study. Clinical Research in Cardiology 99:6, 369-373
CrossRef155
JEAN-YVES LE HEUZEY, GAETANO M. DE FERRARI, DAVID RADZIK, MASSIMO SANTINI, JUNREN ZHU, JEAN-MARC DAVY. (2010) A Short-Term, Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study. Journal of Cardiovascular Electrophysiology 21:6, 597-605
CrossRef156
Carlos G. Santos-Gallego, Jeremías Bayón, Juan José Badimón. (2010) Thrombi of Different Pathologies: Implications for Diagnosis and Treatment. Current Treatment Options in Cardiovascular Medicine 12:3, 274-291
CrossRef157
Ann C. Garlitski, N. A. Mark Estes. (2010) Emerging therapies for atrial fibrillation: is the paradigm shifting?. Journal of Interventional Cardiac Electrophysiology 28:1, 1-4
CrossRef158
Steven Baroletti, Jennifer Catella, Michael Ehle, Judy W. M. Cheng. (2010) Dronedarone. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:2, 94-101
CrossRef159
Ashok J. Shah, Xingpeng Liu, Amir S. Jadidi, Michel Haïssaguerre. (2010) Early management of atrial fibrillation: from imaging to drugs to ablation. Nature Reviews Cardiology 7:6, 345-354
CrossRef160
Fernando D. Testai, Philip B. Gorelick. (2010) New Approaches to Stroke Prevention in Atrial Fibrillation. Current Treatment Options in Cardiovascular Medicine 12:3, 261-273
CrossRef161
JAYAKUMAR SAHADEVAN, ALBERT L. WALDO. (2010) A Perspective on DIONYSOS. Journal of Cardiovascular Electrophysiology 21:6, 606-607
CrossRef162
M.J. Pekka Raatikainen. (2010) Is verapamil a double-edged sword in rate control of paroxysmal atrial fibrillation?. Heart Rhythm 7:5, 584-585
CrossRef163
Gerald V. Naccarelli, Stephen S. Johnston, Jay Lin, Parag P. Patel, Kathy L. Schulman. (2010) Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENA-Like Patients With Atrial Fibrillation/Atrial Flutter in the United States. Clinical Cardiology 33:5, 270-279
CrossRef164
H. Van Herendael, A. Pinter, K. Ahmad, V. Korley, I. Mangat, P. Dorian. (2010) Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators. Europace 12:5, 618-625
CrossRef165
Andrew Tinker, Stephen C Harmer. (2010) K + channels in the heart: new insights and therapeutic implications. Expert Review of Clinical Pharmacology 3:3, 305-319
CrossRef166
Van Gelder, Isabelle C., Groenveld, Hessel F., Crijns, Harry J.G.M., Tuininga, Ype S., Tijssen, Jan G.P., Alings, A. Marco, Hillege, Hans L., Bergsma-Kadijk, Johanna A., Cornel, Jan H., Kamp, Otto, Tukkie, Raymond, Bosker, Hans A., Van Veldhuisen, Dirk J., Van den Berg, Maarten P., . (2010) Lenient versus Strict Rate Control in Patients with Atrial Fibrillation. New England Journal of Medicine 362:15, 1363-1373
Full Text167
Christian Torp-Pedersen, Ole Dyg Pedersen, Lars Køber. (2010) Antiarrhythmic Drugs. Journal of the American College of Cardiology 55:15, 1577-1579
CrossRef168
Dobromir Dobrev, Stanley Nattel. (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. The Lancet 375:9721, 1212-1223
CrossRef169
Licia Polimeni, Ludovica Perri, Mirella Saliola, Stefania Basili, Francesco Violi. (2010) The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Internal and Emergency Medicine 5:2, 91-94
CrossRef170
Bernd-Dieter Gonska. (2010) Atrial fibrillation—rate or rhythm control?. Clinical Research in Cardiology Supplements 5:S1, 11-15
CrossRef171
Nadina Stadler, Thorsten Lewalter. (2010) Innovations in drug treatment of atrial fibrillation. Clinical Research in Cardiology Supplements 5:S1, 47-50
CrossRef172
David Singh, Eugenio Cingolani, George A. Diamond, Sanjay Kaul. (2010) Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 55:15, 1569-1576
CrossRef173
Britta Weidtmann, Thomas Demming, Hendrik Bonnemeier. (2010) The burden of atrial fibrillation. Clinical Research in Cardiology Supplements 5:S1, 57-62
CrossRef174
ERIC N PRYSTOWSKY, JOHN CAMM, GREGORY Y.H. LIP, MAURITS ALLESSIE, JEAN-FRANÇOIS BERGMANN, GÜNTER BREITHARDT, JOSEP BRUGADA, HARRY CRIJNS, PATRICK T. ELLINOR, DANIEL MARK, GERALD NACCARELLI, DOUGLAS PACKER, JUAN TAMARGO. (2010) The Impact of New and Emerging Clinical Data on Treatment Strategies for Atrial Fibrillation. Journal of Cardiovascular Electrophysiologyno-no
CrossRef175
Prakash C. Deedwania, Joel A. Lardizabal. (2010) Atrial Fibrillation in Heart Failure: A Comprehensive Review. The American Journal of Medicine 123:3, 198-204
CrossRef176
David Singh, Steven Singh. (2010) Emerging drugs for atrial fibrillation. Therapy 7:2, 125-132
CrossRef177
Alexander Burashnikov, Charles Antzelevitch. (2010) New developments in atrial antiarrhythmic drug therapy. Nature Reviews Cardiology 7:3, 139-148
CrossRef178
&NA;. (2010) Dronedarone: a guide to its use in atrial fibrillation. Drugs & Therapy Perspectives 26:3, 1-5
CrossRef179
Deirdre A Lane, Gregory YH Lip. (2010) Advances in therapy for atrial fibrillation. Therapy 7:2, 103-105
CrossRef180
Dobromir Dobrev. (2010) Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. Naunyn-Schmiedeberg's Archives of Pharmacology 381:3, 195-206
CrossRef181
Brian Olshansky, Mario Delmar, Gordon F. Tomaselli. (2010) The year in arrhythmias—2009: Part I. Heart Rhythm 7:3, 417-426
CrossRef182
Larissa Fabritz, Paulus Kirchhof. (2010) Predictable and Less Predictable Unwanted Cardiac Drugs Effects: Individual Pre-Disposition and Transient Precipitating Factors. Basic & Clinical Pharmacology & Toxicology 106:3, 263-268
CrossRef183
Thorsten Lewalter. (2010) Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 55:10, 1051-1052
CrossRef184
Niels Voigt, Nadiia Rozmaritsa, Anne Trausch, Thomasz Zimniak, Torsten Christ, Erich Wettwer, Klaus Matschke, Dobromir Dobrev, Ursula Ravens. (2010) Inhibition of IK,ACh current may contribute to clinical efficacy of class I and class III antiarrhythmic drugs in patients with atrial fibrillation. Naunyn-Schmiedeberg's Archives of Pharmacology 381:3, 251-259
CrossRef185
Michael Kühne, David Conen. (2010) Atrial fibrillation in women. Therapy 7:2, 139-146
CrossRef186
Graeme J Hankey. (2010) Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?. Current Opinion in Neurology 23:1, 65-72
CrossRef187
Jennifer M. Belavic. (2010) Drug approvals. The Nurse Practitioner 35:2, 12-23
CrossRef188
Mithilesh K Das, Douglas P Zipes. (2010) Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention. Journal of Cardiovascular Pharmacology1
CrossRef189
Jeremy A. Schafer, Nicole K. Kjesbo, Patrick P. Gleason. (2010) Dronedarone: Current Evidence and Future Questions. Cardiovascular Therapeutics 28:1, 38-47
CrossRef190
Jeong-Gwan Cho. (2010) Recent Advancement in the Management of the Cardiac Arrhythmia. Journal of the Korean Medical Association 53:3, 190
CrossRef191
Marcus L. Koller, Burghard Schumacher. (2010) Medikamentöse Therapie von Herzrhythmusstörungen. Medizinische Klinik 105:1, 26-40
CrossRef192
A. Gil Núñez. (2010) Advances in the Prevention of Cerebral Ischaemia Due to Atrial Fibrillation. Neurología (English Edition) 25:7, 401-408
CrossRef193
Jens Seiler, William G. Stevenson. (2010) Atrial Fibrillation in Congestive Heart Failure. Cardiology in Review 18:1, 38-50
CrossRef194
Gabor Z Duray, Joachim R Ehrlich, Stefan H Hohnloser. (2010) Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. Current Opinion in Cardiology 25:1, 53-58
CrossRef195
Miguel Á. Arias, Marta Pachón, Alberto Puchol, Eduardo Castellanos. (2010) Electrofisiología cardiaca y arritmias. Revista Española de Cardiología 63, 61-72
CrossRef196
Janna Cohen-Lehman, Peter Dahl, Sara Danzi, Irwin Klein. (2010) Effects of amiodarone therapy on thyroid function. Nature Reviews Endocrinology 6:1, 34-41
CrossRef197
Eric N. Prystowsky. (2010) Atrial fibrillation: Dronedarone and amiodarone—the safety versus efficacy debate. Nature Reviews Cardiology 7:1, 5-6
CrossRef198
Ratika Parkash, Atul Verma, Antony SL Tang. (2010) Persistent atrial fibrillation: current approach and controversies. Current Opinion in Cardiology 25:1, 1-7
CrossRef199
Manuel Martínez-Sellés, Tomás Datino, Óscar Díaz-Castro, Ramón López-Palop. (2010) Actualización en cardiología geriátrica. Revista Española de Cardiología 63, 17-28
CrossRef200
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. European Heart Journal 30:24, 2969-2980
CrossRef201
Rakesh Gopinathannair, Renee M. Sullivan, Brian Olshansky. (2009) Tachycardia-mediated cardiomyopathy: Recognition and management. Current Heart Failure Reports 6:4, 257-264
CrossRef202
Peter Kowey. (2009) Gaps in the ARB Knowledge Base: Are ARBs Effective Anti-Atrial Fibrillation Agents?. The Journal of Clinical Hypertension 11, S48-S51
CrossRef203
Silvia A. Eskes, Wilmar M. Wiersinga. (2009) Amiodarone and thyroid. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, 735-751
CrossRef204
Bramah Singh. (2009) Atrial fibrillation: from ion channels to bedside treatment options. Journal of Electrocardiology 42:6, 660-670
CrossRef205
G. Z. Duray, J. Schmitt, S. Richter, C. W. Israel, S. H. Hohnloser. (2009) Arrhythmic death in implantable cardioverter defibrillator patients: a long-term study over a 10 year implantation period. Europace 11:11, 1462-1468
CrossRef206
Joachim R. Ehrlich, Stefan H. Hohnloser. (2009) Milestones in the management of atrial fibrillation. Heart Rhythm 6:11, S62-S67
CrossRef207
JUAN SHU, JUN ZHOU, CHINMAY PATEL, GAN-XIN YAN. (2009) Pharmacotherapy of Cardiac Arrhythmias-Basic Science for Clinicians. Pacing and Clinical Electrophysiology 32:11, 1454-1465
CrossRef208
H.-J. Trappe. (2009) Antiarrhythmische Therapie mit Amiodaron bei tachykarden Rhythmusstörungen. Intensivmedizin und Notfallmedizin 46:8, 563-572
CrossRef209
Orson Go, Clive Rosendorff. (2009) Hypertension and atrial fibrillation. Current Cardiology Reports 11:6, 430-435
CrossRef210
R. H. Falk, A. J. Camm. (2009) Rethinking the reasons to treat atrial fibrillation? The role of dronedarone in reducing cardiovascular hospitalizations. European Heart Journal 30:20, 2438-2440
CrossRef211
Kapil Kumar, Peter J. Zimetbaum. (2009) New and emerging antiarrhythmic drugs for atrial fibrillation: What may become available to the clinician in the near future. Current Treatment Options in Cardiovascular Medicine 11:5, 373-380
CrossRef212
Pieter De Meester, Vincent Thijs, Rik Willems, Werner Budts. (2009) Percutaneous closure of the left atrial appendage in atrial fibrillation: an alternative if standard treatment fails?. Interventional Cardiology 1:1, 119-131
CrossRef213
Kenan Yalta, Okan Onur Turgut, Mehmet Birhan Yılmaz, Ahmet Yılmaz, Izzet Tandogan. (2009) Dronedarone: A Promısıng Alternatıve for the Management of Atrıal Fıbrıllatıon. Cardiovascular Drugs and Therapy 23:5, 385-393
CrossRef214
Richard L. Page, Bashar Hamad, Peter Kirkpatrick. (2009) Dronedarone. Nature Reviews Drug Discovery 8:10, 769-770
CrossRef215
Paul S. Chan, Brahmajee K. Nallamothu, Hakan Oral. (2009) Amiodarone or Dronedarone for Atrial Fibrillation. Journal of the American College of Cardiology 54:12, 1096-1098
CrossRef216
Jonathan P. Piccini, Vic Hasselblad, Eric D. Peterson, Jeffrey B. Washam, Robert M. Califf, David F. Kong. (2009) Comparative Efficacy of Dronedarone and Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation. Journal of the American College of Cardiology 54:12, 1089-1095
CrossRef217
Danielle Garcia, Angela Cheng-Lai. (2009) Dronedarone. Cardiology in Review 17:5, 230-234
CrossRef218
Gregory M. Marcus, Edmund Keung, Melvin M. Scheinman. (2009) The Year in Review of Clinical Cardiac Electrophysiology. Journal of the American College of Cardiology 54:9, 777-787
CrossRef219
Sheridan M. Hoy, Susan J. Keam. (2009) Dronedarone. Drugs 69:12, 1647-1663
CrossRef220
Dimpi Patel, Andrea Natale, Luigi Di Biase, J David Burkhardt, Yan Wang, Javier E Sanchez, Rodney P Horton, Mohammed Khan. (2009) Catheter ablation for atrial fibrillation: a promising therapy for congestive heart failure. Expert Review of Cardiovascular Therapy 7:7, 779-787
CrossRef221
Patricia A. Howard. (2009) Cardiovascular Therapeutics - Dronedarone: Emergence of a New Therapeutic Option for the Treatment of Atrial Fibrillation. Hospital Pharmacy 44:7, 562-565
CrossRef222
J.-Y. Le Heuzey. (2009) The risk of antiarrhythmic drugs in atrial fibrillation: 20 years of controversies. Europace 11:7, 840-841
CrossRef223
P. Kirchhof, J. Bax, C. Blomstrom-Lundquist, H. Calkins, A. J. Camm, R. Cappato, F. Cosio, H. Crijns, H.-C. Diener, A. Goette, C. W. Israel, K.-H. Kuck, G. Y.H. Lip, S. Nattel, R. L. Page, U. Ravens, U. Schotten, G. Steinbeck, P. Vardas, A. Waldo, K. Wegscheider, S. Willems, G. Breithardt. (2009) Early and comprehensive management of atrial fibrillation: Proceedings from the 2nd AFNET/EHRA consensus conference on atrial fibrillation entitled 'research perspectives in atrial fibrillation'. Europace 11:7, 860-885
CrossRef224
(2009) Dronedarone in Atrial Fibrillation. New England Journal of Medicine 360:23, 2479-2481
Full Text225
B. Lüderitz. (2009) Muss jedes Vorhofflimmern behandelt werden?. Herzschrittmachertherapie + Elektrophysiologie 20:2, 56-60
CrossRef226
J. Brachmann, A.-M. Sinha. (2009) Dronedarone: Das neue Antiarrhythmikum?. Herzschrittmachertherapie + Elektrophysiologie 20:2, 73-75
CrossRef227
B.-D. Gonska, H.J. Bauerle, T. Japha. (2009) Vorhofflimmerablation: Wer kommt in Frage?. Herzschrittmachertherapie + Elektrophysiologie 20:2, 76-81
CrossRef228
Robert W. Bolderman, J.J. Rob Hermans, Jos G. Maessen. (2009) Determination of the class III antiarrhythmic drugs dronedarone and amiodarone, and their principal metabolites in plasma and myocardium by high-performance liquid chromatography and UV-detection. Journal of Chromatography B 877:18-19, 1727-1731
CrossRef229
Alexandra King. (2009) Is dronedarone a new option for AF patients?. Nature Reviews Cardiology 6:5, 326-326
CrossRef230
Joachim R. Ehrlich, Stanley Nattel. (2009) Novel Approaches for Pharmacological Management of Atrial Fibrillation. Drugs 69:7, 757-774
CrossRef231
B. Lüderitz. (2009) Pharmakologische Konzepte zur Therapie des Vorhofflimmerns. Clinical Research in Cardiology Supplements 4:S2, 170-175
CrossRef232
A. John Camm, Irina Savelieva. (2009) Atrial Fibrillation: A4 study: proof of concept?. Nature Reviews Cardiology 6:5, 332-334
CrossRef233
Suresh Krishnamoorthy, Gregory YH Lip. (2009) Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. Expert Review of Cardiovascular Therapy 7:5, 473-481
CrossRef234
Stefan H. Hohnloser. (2009) Nuevas perspectivas farmacológicas en pacientes con fibrilación auricular: el ensayo ATHENA. Revista Española de Cardiología 62:5, 479-481
CrossRef235
Zimetbaum, Peter J., . (2009) Dronedarone for Atrial Fibrillation — An Odyssey. New England Journal of Medicine 360:18, 1811-1813
Full Text236
(2009) Trial watch: Novel antiarrhythmic agent shows promise in Phase III trial. Nature Reviews Drug Discovery 8:4, 266-266
CrossRef
- Letters
